In a double‐blind, prospective, randomized trial, the healing effect of somatostatin was compared with that of cimetidine in 67 patients with endoscopically confirmed duodenal ulcer with active bleeding (33 patients were treated with somatostatin, 34 with cimetidine). Intravenous infusion of either drug was administered for 48 or 72 b. Somatostatin bad a bigger rate of control of bleeding (30 vs. 24 patients at 72 h; p < 0.05) and bad less mean transfusion requirements (4.4 vs. 5.8 units; p < 0.01). Need for surgical intervention and the mortality figures show a trend in favor of somatostatin. There was no difference in rebleeding rate.
|Number of pages||4|
|Journal||The American Journal of Gastroenterology|
|Publication status||Published - Jan 1989|
ASJC Scopus subject areas